Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
Bone Marrow Transplant. 2017 Sep;52(9):1280-1287. doi: 10.1038/bmt.2017.96. Epub 2017 Jun 5.
In 8/8 HLA-matched unrelated donor (UD) hematopoietic cell transplants (HCT), HLA-DPB1 mismatches between alleles from different T-cell epitope (TCE) groups (non-permissive mismatches) are associated with significantly higher risks of mortality compared with those between alleles from the same TCE group (permissive mismatches); however, the relevance of mismatch directionality, that is (host vs graft (uni-directional HvG), graft vs host (uni-directional GvH) or both (bi-directional) in the non-permissive setting is unknown. We show here significantly higher in vitro relative responses (RR) to bi-directional mismatches compared with uni-directional HvG or GvH mismatches in a total of 420 one-way mixed lymphocyte reactions between 10/10 matched pairs (RR 27.5 vs 7.5 vs 15.5, respectively, P<0.001). However, in 3281 8/8 matched UD HCT for leukemia or myelodysplastic syndrome, the hazards of transplant-related mortality (TRM) were similar for uni-directional HvG or GvH mismatches and bi-directional mismatches (hazard ratio (HR) 1.32, P=0.001 vs HR 1.28, P=0.005 and HR 1.34, P=0.046), compared with permissive mismatches. Similar results were observed for overall survival. No statistical differences between the uni- and the bi-directional non-permissive groups were detected in pairwise comparisons for any of the outcomes tested. We conclude that consideration of directionality does not improve risk stratification by non-permissive HLA-DPB1 TCE mismatches in UD searches.
在 8/8 人类白细胞抗原(HLA)匹配的无关供者(UD)造血细胞移植(HCT)中,来自不同 T 细胞表位(TCE)组的 HLA-DPB1 等位基因之间的错配(非允许性错配)与来自同一 TCE 组的等位基因之间的错配(允许性错配)相比,死亡率显著更高;然而,非允许性错配中错配方向的相关性,即(宿主对移植物(单向 HvG)、移植物对宿主(单向 GvH)或两者(双向)的相关性尚不清楚。我们在此显示,在总共 420 次 10/10 匹配对之间的单向混合淋巴细胞反应中,与单向 HvG 或 GvH 错配相比,双向错配的体外相对反应(RR)显著更高(RR 分别为 27.5、7.5 和 15.5,P<0.001)。然而,在 3281 例白血病或骨髓增生异常综合征的 8/8 匹配 UD HCT 中,与允许性错配相比,单向 HvG 或 GvH 错配和双向错配的移植相关死亡率(TRM)的危险比(HR)相似(HR 分别为 1.32,P=0.001,HR 为 1.28,P=0.005 和 HR 为 1.34,P=0.046)。对于总生存情况也观察到了类似的结果。在任何测试的结果的成对比较中,单向和双向非允许性组之间没有检测到统计学差异。我们得出的结论是,在 UD 搜索中,考虑方向性并不能改善非允许性 HLA-DPB1 TCE 错配的风险分层。